68ganota-anti-mmr-vhh2
mAbexperimentalImaging agent
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Nov 5, 2019 (NCT04168528)
Timeline
Indications
Studied for
- Atherosclerosis · Phase 2
- Breast Neoplasms · Phase 1/Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 2
- Carotid Stenosis · Phase 2
- Head and Neck Neoplasms · Phase 2
- Heart Diseases · Phase 2
- Hodgkin Disease · Phase 2
- Lymphohistiocytosis, Hemophagocytic · Phase 2
- Lymphoma, Non-Hodgkin · Phase 2
- Melanoma · Phase 1/Phase 2
- Neoplasms · Phase 2
- Sarcoidosis · Phase 2
- Squamous Cell Carcinoma of Head and Neck · Phase 2
Mechanism of action
- Macrophage mannose receptor 1INHIBITOR
MRC1 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
- Imaging
- 68-Gallium
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05933239 | Phase 2 | Mar 30, 2023 | Free University of Brussels |
| NCT04758650 | Phase 2 | Jan 26, 2021 | Free University of Brussels |
| NCT04168528 | Phase 1/Phase 2 (Phase 2) | Nov 5, 2019 | Free University of Brussels, Kom Op Tegen Kanker |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Free University of Brussels | Academic/Hospital | 3 | 3 | 1 | 2019 |
| Kom Op Tegen Kanker | Academic/Hospital | 1 | 0 | 1 | 2019 |
2 organizations
Page 1 / 1